Objective
To evaluate whether the immunomodulatory drug thymosin α1 reduces mortality in adults with sepsis.Design
Multicentre, double blinded, placebo controlled phase 3 trial.Setting
22 centres in China, September 2016 to December 2020.Participants
1106 adults aged ...
